Trial Profile
A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Brain metastases; Solid tumours
- Focus Therapeutic Use
- 07 Mar 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 25 Oct 2021 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 25 Oct 2021 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.